Spread of novel expanded-spectrum β-lactamases in Enterobacteriaceae in a university hospital in the Paris area, France  by Lartigue, M.-F. et al.
RESEARCH NOTE
Spread of novel expanded-spectrum
b-lactamases in Enterobacteriaceae in a
university hospital in the Paris area, France
M.-F. Lartigue, N. Fortineau and
P. Nordmann
Service de Bacte´riologie-Virologie, Hoˆpital de
Biceˆtre, Assistance Publique ⁄Hoˆpitaux de Paris,
Faculte´ de Me´decine Paris-Sud, K.-Biceˆtre,
France
ABSTRACT
In 2002, 28 non-duplicate enterobacterial iso-
lates producing extended-spectrum b-lactamases
(ESBLs) were collected from infected patients at
the Biceˆtre Hospital in Paris, France. Escherichia
coli was the predominant ESBL-positive entero-
bacterial species, comprising ten (36%) of the
isolates. CTX-M enzymes (CTX-M-3, CTX-M-10,
CTX-M-14 and CTX-M-15) were produced by 11
(39%) of the isolates (six E. coli, two Enterobacter
cloacae, one Enterobacter aerogenes, one Proteus
mirabilis and one Citrobacter freundii). Other
ESBLs, such as VEB-1 and PER-1, were also
detected, but less frequently.
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The emergence of novel extended-spectrum
b-lactamases (ESBLs) that are inhibited by clavul-
anic acid, but are not TEM or SHV enzymes, has
been reported in Enterobacteriaceae [1,2]. These
enzymes are of the CTX-M, PER, VEB and
GES ⁄ IBC types. The CTX-M b-lactamases are
now widespread in both nosocomial and com-
munity-acquired pathogens [1], and include at
least 40 b-lactamases divided into five major
subgroups according to amino-acid sequence
identity [1]. The present study describes a 1-year
retrospective study (January to December 2002)
designed to evaluate the prevalence of these novel
ESBLs in Enterobacteriaceae isolated from
patients admitted to the Bicetre hospital (Paris
area, France).
In total, 3444 non-repetitive clinical isolates of
Enterobacteriaceae (a single isolate of the same
species ⁄patient) were isolated consecutively from
the infection sites of hospitalised patients at least
24 h after admission. These isolates were screened
for ESBLs, based on the results of tests for
resistance to expanded-spectrum cephalosporins
and double-disk antibiotic susceptibility tests [3].
Synergy tests were performed with ceftazidime-,
cefotaxime-, aztreonam- and ticarcillin–clavulanic
acid-containing disks on Mueller–Hinton agar
plates, with and without cloxacillin (250 mg ⁄L)
[3]. Susceptibility to other antibiotics (gentamicin,
tobramycin, netilmicin, amikacin, trimethoprim–
sulphamethoxazole, nalidixic acid and ciprofloxa-
cin) was determined by disk-diffusion antibio-
gram [3]. Isolates were identified with the API 20E
system (bioMe´rieux, Marcy-L’Etoile, France) [4].
b-Lactamase genes were detected by PCR using
specific primers for the blaTEM, blaSHV, blaCTX-M,
blaVEB, blaPER and blaGES genes [3,4]. To avoid
confusion caused by the concomitant sequence of
the chromosomally located blaSHV-1 gene in
Klebsiella pneumoniae, any plasmid-mediated
blaSHV genes from K. pneumoniae isolates were
transformed into Escherichia coli DH10B by elec-
troporation [3] following isolation of plasmid
DNA, with subsequent PCR analysis of the
transformants. PCR products were sequenced as
described previously [3].
Of the 3444 isolates, 28 (0.8%) had an ESBL
phenotype according to the results of the double-
disk antibiotic susceptibility tests [3]. The ESBL
frequency was low compared with that of other
hospitals in France, as exemplified by results from
another French region, Auvergne [5]. Thirteen of
the 28 ESBL-producers were cefotaxime- and ceft-
azidime-resistant. The ESBL-producing isolates
were recovered mostly from urine, but also from
pus, the respiratory tract, intravascular catheters
and bile specimens (Table 1). No isolate from blood
cultures was positive for ESBL production.
Corresponding author and reprint requests: P. Nordmann,
Service de Bacte´riologie-Virologie, Hoˆpital de Biceˆtre, Assist-
ance Publique ⁄Hoˆpitaux de Paris, Universite´ Paris XI, 78, rue
du Ge´ne´ral Leclerc, 94275 K.-Biceˆtre cedex, France
E-mail: nordmann.patrice@bct.ap-hop-paris.fr
588 Clinical Microbiology and Infection, Volume 11 Number 7, July 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 577–596
E. coli was the predominant ESBL-positive
species of enterobacteria in 2002 (10 ⁄ 28 isolates;
Table 1), whereas, in French hospitals located
outside the Paris area, the most common ESBL-
producer in 2002 was Enterobacter aerogenes [4,5].
Other ESBL-producing isolates were four
K. pneumoniae, four Enterobacter cloacae, three
Klebsiella oxytoca, two Ent. aerogenes, two Proteus
mirabilis, one Citrobacter koseri, one Citrobacter
freundii and one Providencia stuartii (Table 1).
The prevalence of the ESBL producers according
to species was 0.5% for E. coli, 1.4% for
K. pneumoniae, 1.5% for Ent. cloacae, 2.6% for
K. oxytoca, 0.9% for P. mirabilis, 3.6% for Ent.
aerogenes, 1.6% for C. freundii, 1.8% for C. koseri,
and 6.2% for P. stuartii.
One-third of ESBLs detected were CTX-M
enzymes. As opposed to hospitals located out-
side the Paris area, where TEM-3 and TEM-24
were the most frequent ESBLs (90%) during the
same period [5,6], only one-third of ESBLs in
the present study were TEM enzymes. These
results could be explained by the absence of any
outbreak involving an ESBL-producer at the
Biceˆtre Hospital, which was not the case in
hospitals located outside the Paris area [5,6].
The CTX-M enzymes detected were of four
different types: CTX-M-3 (n = 3), CTX-M-10
(n = 1), CTX-M-14 (n = 2) and CTX-M-15
(n = 5) [7] (Table 1), belonging to two of the
five CTX-M clusters, i.e., the CTX-M-1 and CTX-
M-9 clusters. CTX-M-15 was the predominant
CTX-M in Biceˆtre Hospital, as found also in four
other hospitals in Paris, and in the UK during
the same period [4,8]. Sequence analysis of CTX-
M-15 revealed an Asp240Gly substitution, com-
pared to CTX-M-3, that conferred resistance to
ceftazidime [9]. This is an uncommon property
for CTX-M enzymes, since these enzymes were
originally termed CTX-M to highlight their
greater activity against cefotaxime than against
ceftazidime.
Table 1. Characteristics of clinical isolates producing extended-spectrum b-lactamases
Isolate Ward Specimen
b-Lactamasea
Non-b-lactam resistance
phenotypebCTX-M TEM SHV Others
E. coli MAZ Gerontology Urine CTX-M-15 TEM-1 CIP
E. coli DOS Surgical
intensive
care unit
Catheter CTX-M-15 TEM-1 GEN ⁄TOB ⁄NET ⁄ SXT ⁄CIP
E. coli JUR Surgical
intensive
care unit
Urine CTX-M-15 TEM-1 GEN ⁄TOB ⁄NET ⁄AMK ⁄ SXT ⁄CIP
E. coli DIA Gastroenterology Urine CTX-M-10 SXT
E. coli PHU Urology Urine CTX-M-14 TEM-1 GEN ⁄TOB ⁄NET ⁄ SXT ⁄CIP
E. coli HUA Urology Urine CTX-M-14 TEM-1 TOB ⁄NET ⁄AMK ⁄ SXT ⁄CIP
E. coli HAN Gerontology Urine TEM-24 TOB ⁄NET ⁄AMK ⁄ SXT ⁄CIP
E. coli BOU Gerontology Urine TEM-24 TOB ⁄NET ⁄AMK ⁄ SXT ⁄CIP
E. coli LEG Gerontology Urine TEM-24 TOB ⁄NET ⁄AMK ⁄ SXT ⁄CIP
E. coli CHA Medical
intensive
care unit
Bile SHV-2a GEN ⁄TOB
K. pneumoniae KAC Gastroenterology Urine SHV-5 GEN ⁄TOB ⁄NET ⁄AMK ⁄ SXT
K. pneumoniae BIZ Gastroenterology Urine SHV-5 GEN ⁄TOB ⁄NET ⁄AMK ⁄ SXT ⁄CIP
K. pneumoniae HEN Orthopaedic surgery Urine TEM-1 SHV-5 GEN ⁄TOB ⁄NET ⁄AMK ⁄ SXT ⁄CIP
K. pneumoniae ARA Gastroenterology Urine SHV-2a GEN ⁄TOB
E. cloacae MET Cardiology Urine CTX-M-15 TEM-1 GEN ⁄TOB ⁄NET ⁄ SXT ⁄CIP
E. cloacae TOM Urology Urine CTX-M-3 TEM-24 TOB ⁄NET ⁄AMK ⁄ SXT ⁄CIP
E. cloacae GOC Emergency Urine TEM-1 VEB-1 GEN ⁄TOB ⁄NET ⁄AMK ⁄CIP
E. cloacae LAC Urology Pus TEM-24 TOB ⁄NET ⁄AMK ⁄ SXT ⁄CIP
K. oxytoca BOC Gastroenterology Pus TEM-3 TOB ⁄NET ⁄AMK ⁄CIP
K. oxytoca NOG Paediatric intensive
care unit
Catheter TEM-3 TOB ⁄NET ⁄AMK ⁄ SXT ⁄NAL
K. oxytoca PER Paediatric intensive
care unit
Pus SHV-2a GEN ⁄TOB ⁄NET
C. freundii NAO Digestive surgery Urine CTX-M-3 TEM-1 GEN ⁄TOB ⁄NET ⁄ SXT ⁄CIP
Ent. aerogenes STE Nephrology Pus CTX-M-15 SHV-4 TOB ⁄NET ⁄AMK ⁄ SXT ⁄CIP
Ent. aerogenes ZAQ Neurology Pus TEM-24 TOB ⁄NET ⁄AMK ⁄ SXT ⁄CIP
P. mirabilis NAO Surgical intensive
care unit
Respiratory tract CTX-M-3 TEM-1 GEN ⁄TOB ⁄NET ⁄AMK ⁄ SXT
P. mirabilis BRO Gastroenterology Urine TEM-3 GEN ⁄TOB ⁄NET ⁄CIP
P. stuartii BEN Neurology Pus PER-1 GEN ⁄TOB ⁄NET ⁄NAL
C. koseri BEL Urology Pus TEM-3 TOB ⁄NET ⁄AMK ⁄CIP
aESBLs are indicated by bold type.
bGEN, gentamicin; TOB, tobramycin; NET, netilmicin; AMK, amikacin; SXT, trimethoprim–sulphamethoxazole; NAL, nalidixic acid; CIP, ciprofloxacin.
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This latter result indicates that detection of a
CTX-M-producer cannot be based solely on a
phenotype of resistance to cefotaxime and sus-
ceptibility to ceftazidime. In the present study,
E. coli produced 55% of the CTX-M enzymes (six
of 11), and CTX-M enzymes represented 60% of
the ESBLs produced by E. coli (six of ten), similar
to the results from another Paris hospital (Tenon
Hospital) in 2001 and 2002 (50%) [4]. The five
other CTX-M enzymes were identified in
Ent. cloacae (two isolates), C. freundii, Ent. aerogenes
and P. mirabilis. The CTX-M genes were always
associated with insertion sequence ISEcp1-like
elements located upstream of the b-lactamase
gene (data not shown), which are probably
responsible for expression and mobilisation [10].
A VEB-1 b-lactamase was identified in a single
Ent. cloacae isolate, and a PER-1 ESBL was
detected in a single P. stuartii isolate. This latter
enzyme has been described previously in two
species of Enterobacteriaceae (Salmonella enterica
serotype Typhimurium and Proteus mirabilis)
[11,12], but this is the first report of PER-1 in
P. stuartii. No ESBLs of the GES-1 ⁄ 2 type were
identified.
The TEM-type enzymes detected were either
TEM-24 (six isolates) or TEM-3 (four isolates)
(Table 1). Random amplified polymorphic DNA
(RAPD) analysis using primers ERIC-2, A3, 628
and 6MW showed that the two Ent. aerogenes
isolates were not clonally related, and that the
Ent. aerogenes isolate producing TEM-24 from the
present study was different from the epidemic
Ent. aerogenes strain from Clermont-Ferrand [5]
that has spread in western Europe. In contrast to
other French hospitals, no clonal dissemination of
strains of Ent. aerogenes producing TEM-24 was
observed [5,6], but this ESBL was identified in
E. coli and Enterobacter cloacae). The SHV-type
ESBLs were SHV-2a, SHV-4 and SHV-5, most of
which were identified in K. pneumoniae (Table 1).
Two isolates produced ESBLs in addition to a
CTX-M enzyme: one Ent. aerogenes isolate pro-
duced both CTX-M-15 and SHV-4, and one
Ent. cloacae isolate produced both CTX-M-3 and
TEM-24 (Table 1). Ten of the 28 isolates also
produced a TEM-1 b-lactamase, eight of which
were associated with a CTX-M enzyme (Table 1),
as reported previously [4].
When ESBLs were first identified in the mid-
1980s, they were predominantly of the TEM type.
In the mid-1990s in Europe, SHV-type enzymes
were the most frequent ESBLs, and K. pneumoniae
was the predominant species for ESBL pro-
duction. TEM-24 b-lactamase produced by
Ent. aerogenes was the most frequent ESBL in
France in 1998 [5,6,13]. Interestingly, the present
study found that one-third of ESBLs in Entero-
bacteriaceae recovered from clinical infections in
a university hospital in the Paris area were
CTX-M enzymes, with the blaCTX-M-15 gene being
predominant, a situation that mirrors the current
trend in the UK [8]. It remains to be determined
why the CTX-M enzymes have spread world-
wide, and why E. coli is becoming the most
important enterobacterial species in this respect.
Furthermore, other rare ESBLs such as VEB-1 and
PER-1 enzymes were identified in this study,
indicating that ESBLs other than CTX-M enzymes
may also emerge in Enterobacteriaceae in the near
future.
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ABSTRACT
This report describes the first occurrence of the
DHA-1 ampC b-lactamase gene in Proteus mirabilis.
The organism was isolated from the vaginal
flora of a pregnant woman in a French hospital.
The DHA-1 b-lactamase gene was identified
on the basis of phenotypic characteristics,
PCR amplification and sequencing. Antagonism
between cefoxitin and the other cephalosporins
suggested inducible production of the DHA-1
enzyme.
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Proteus mirabilis is a Gram-negative bacterium
that is naturally sensitive to ampicillin and
cephalosporins because of the lack of a chromo-
somal ampC b-lactamase gene. However, this
organism can become resistant to ampicillin by
acquisition of a TEM-type penicillinase. Inhibitor-
resistant TEM enzymes and resistance to broad-
spectrum cephalosporins, resulting from the
acquisition of TEM-type extended-spectrum
b-lactamases, have also been described in P. mira-
bilis [1,2]. Most recently, class C b-lactamases,
conferring resistance to 7a-methoxy-cephalospo-
rins, have appeared in this species [3,4]. The ampC
genes described in P. mirabilis belong to the ACC
or CMY families, related to the Hafnia alvei and
Citrobacter freundii ampC chromosomal genes,
respectively, and have been reported to be either
plasmid-encoded or inserted on the chromosome
(probably by transposition) in P. mirabilis [3–6].
The DHA-1 plasmid-encoded ampC gene was first
described in Salmonella enterica in Saudi Arabia
(with recent spread to the UK), and in Klebsiella
pneumoniae [7–11]. The present report describes
the first occurrence of a DHA-1 ampC gene in
P. mirabilis.
The patient concerned was a pregnant woman,
aged 34 years, who was admitted to the maternity
ward of Robert-Debre´ Hospital, Paris. A P. mira-
bilis isolate resistant to cephalothin was isolated
from a vaginal swab taken after 37 weeks of
amenorrhoea. The patient gave birth by Caesarian
section after 40 weeks of amenorrhoea to a healthy
infant that was not colonised by P. mirabilis. Two
days after delivery, the patient had a fever (38.6C)
and was treated with cefotaxime for 3 days, but
with no documented infection (blood and urine
cultures gave negative results). Ten days after
delivery, a P. mirabilis isolate resistant to cephalo-
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